CymaBay Therapeutics Inc (DELISTED) (CBAY:DL)
32.48
0.00 (0.00%)
USD |
NASDAQ |
Mar 25, 16:00
CymaBay Therapeutics Revenue (Quarterly): 0.057M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.057M |
| September 30, 2023 | |
| June 30, 2023 | 31.02M |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 |
| Date | Value |
|---|---|
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 5.207M |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | 4.793M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.057M
Minimum
Dec 2023
31.02M
Maximum
Jun 2023
15.54M
Average
15.54M
Median
Revenue (Quarterly) Benchmarks
| Gilead Sciences Inc | 6.686B |
| Assure Holdings Corp | 0.029M |
| Societal CDMO Inc (DELISTED) | 27.72M |
| AN2 Therapeutics Inc | -- |
| Madrigal Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -41.90M |
| Total Expenses (Quarterly) | 42.56M |
| EPS Diluted (Quarterly) | -0.37 |
| Enterprise Value | 3.443B |
| Profit Margin (Quarterly) | -73.51K% |
| Earnings Yield | -3.05% |
| Normalized Earnings Yield | -3.048 |